Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Yesterday, May 21, 2014, 140 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $401.00 to $744,000,000.00. Highlighted Stocks Traded by Insiders: Impax Laboratories (IPXL) - FREE Research Report Terreri Peter R, who is Director at Impax Laboratories, sold 666 shares at $26.07 on May 21, 2014. Following this transaction, the Director owned 44,520 shares meaning that the stake was reduced by 1.47% with the 666-share transaction. The shares most recently traded at $27.29, up $1.22, or 4.47% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:
4-Week # shares sold: 228,235
12-Week # shares sold: 232,235
24-Week # shares sold: 235,235
The average volume for Impax Laboratories has been 777,400 shares per day over the past 30 days. Impax Laboratories has a market cap of $1.9 billion and is part of the health care sector and drugs industry. Shares are up 5.37% year-to-date as of the close of trading on Wednesday. Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The company has a P/E ratio of 2666.0. Currently, there are 2 analysts who rate Impax Laboratories a buy, 2 analysts rate it a sell, and 4 rate it a hold. Exclusive Offer: Get the latest Stock Analysis on IPXL - FREETheStreet Quant Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.